Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

PHASE4CompletedINTERVENTIONAL

Enrollment

149

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

July 23, 2025

Study Completion Date

July 23, 2025

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Risedronate Sodium 35 MG [Actonel]

Risendronate Sodium Tab. 35mg, orally, once weekly

DRUG

Calcium Vitamin D combination

orally, once daily for concomitant drug

Trial Locations (1)

Severance Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY